Effectiveness and Safety of OviTex® PRS in Breast Reconstruction
← catalyst calendarNCT07135596 · readout ≤ 1,410 d
Sponsored by Tela Bio Inc (industry) · TELA — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
235estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-10 | actual | When the study began enrolling |
| Primary completion | Jun 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2034 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Reconstruction
Intervention
- Device: OviTex PRS
Primary outcomes
what the primary-completion date above is the date OFReconstructive Failure Rate
measured From enrollment to 12 months
Major Complication Rate
measured From enrollment to 12 months
Permalink · TELA's whole pipeline · Catalyst calendar · Every registered study · What changed